Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2025-11-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company (葵花药业集团股份有限公司) about the progress of using idle self-owned funds for cash management. It includes specifics about investment amounts, types of financial products purchased, risk control measures, and the impact on the company. The document is an update on financing activities related to cash management, not a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly/yearly results. The content fits best under Capital/Financing Update (CAP) as it details the company's financing and investment activities with idle funds.
2025-11-28 Chinese
关于注销全资子公司的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of the cancellation (注销) of a wholly-owned subsidiary by the company. It includes details about the board meeting decision, the completion of the deregistration process, and assurances about the impact on the company and shareholders. There is no financial data, no detailed report, and the document is relatively short (730 characters). It is clearly an official announcement about a corporate action (subsidiary cancellation) rather than a financial report or detailed management discussion. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-11-25 Chinese
关于2022年员工持股计划股份出售完毕暨终止的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion and termination of the company's 2022 employee stock ownership plan, including details about stock sales, lock-up periods, and compliance with regulations. It does not contain financial statements or detailed financial performance data. The document is relatively short (1526 characters) and serves as a formal notification of the status and conclusion of a capital-related plan. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as employee stock plans and share sales.
2025-11-24 Chinese
第五届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 13th meeting of the 5th Board of Directors of the company. It details the meeting date, attendance, and the approval of a product development project. There is no financial data or comprehensive report content, only a formal announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short and focused on board meeting resolutions, not a full report or financial disclosure.
2025-11-18 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products purchased, risk control measures, and the impact on the company. The document is a formal public disclosure about the company's cash management activities and investment progress, including tables of transactions and risk assessments. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report publication announcement since it contains substantive information about the cash management activities rather than just announcing a report's release. The document fits best into the category of Capital/Financing Update (CAP), as it provides updates on the company's use of funds and financial management activities.
2025-11-17 Chinese
关于复方聚乙二醇(3350)电解质散获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving a drug registration certificate from the national drug regulatory authority. It details the drug's name, composition, registration classification, approval number, and intended use. The document also includes a risk warning related to the new product's market launch. There is no financial data, no mention of annual or quarterly reports, no discussion of management changes, no voting results, and no regulatory certifications or legal proceedings. The document is an official announcement of a regulatory approval event relevant to the company's product portfolio. It does not fit into financial report categories but is a regulatory announcement about a product approval. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-11-14 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.